Cancer News and Research

Latest Cancer News and Research

Lifeline Biotechnologies to establish a demonstration site for its First Warning System

Lifeline Biotechnologies, Inc. today announced that it is preparing to establish a demonstration site for its First Warning System to be located in Reno, Nevada.

26 Aug 2009

Gloucester Pharmaceuticals raises funds for the development of romidepsin

Gloucester Pharmaceuticals today announced that it has raised $29 million in a Series D financing. The proceeds will be used to support the ongoing development of romidepsin, a novel histone deacetylase (HDAC) inhibitor for the treatment of T-cell lymphomas and other hematologic malignancies.

26 Aug 2009

Increased risk of death for men with heart conditions undergoing RT with hormone therapy for prostate cancer

Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or along with radiation therapy for treatment of prostate cancer have an associated increased risk of death, according to a study in the August 26 issue of JAMA.

26 Aug 2009

Duodenal obstruction observed after selective transcatheter arterial embolization for a duodenal diverticular hemorrhage

Ho Jeong and his colleague from Korea presented a case of duodenal obstruction after successful selective transcatheter arterial embolization (TAE) for a duodenal diverticular hemorrhage. Their study will be published on August 14, 2009 in the World Journal of Gastroenterology.

26 Aug 2009

Tamoxifen drug poses increased risk of developing ER negative breast cancer

While long-term tamoxifen use among breast cancer survivors decreases their risk of developing the most common, less aggressive type of second breast cancer, such use is associated with a more than four-fold increased risk of a more aggressive, difficult-to-treat type of cancer in the breast opposite, or contralateral, to the initial tumor.

26 Aug 2009

Profectus BioSciences to conduct proof-of-concept studies with its rVSV vector technology

Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates for serious chronic infections, announced today it has entered into a research collaboration agreement with the PATH Malaria Vaccine Initiative (MVI) to conduct proof-of-concept studies with its proprietary, recombinant vesicular stomatitis virus (rVSV) vector technology as a preventative malaria vaccine.

26 Aug 2009

Research indicates that acute hepatocellular injury in cholelithiasis and cholecystitis without choledocholithiasis is mild and transient

Acute hepatocellular injury is a commonly encountered phenomenon in patients with cholelithiasis and concomitant common bile duct (CBD) stones. However, in clinical practice, it seemed to occur also in cholelithiasis patients without evidence of CBD stones. Its incidence and final outcome necessitated clarification.

26 Aug 2009

U.S. Patent Office’s patent issuance provides extensive protection to BDSI's drug delivery technology platforms

BioDelivery Sciences International, Inc. today announced the issuance of United States Patent 7,579,019, which will provide additional patent exclusivity for both ONSOLIS and BDSI’s BEMA drug delivery technology platform until at least 2019.

26 Aug 2009

MicroRNAs in saliva could aid in the detection of oral cancer

Researchers continue to add to the diagnostic alphabet of saliva by identifying the presence of at least 50 microRNAs that could aid in the detection of oral cancer, according to a report in Clinical Cancer Research, a journal of the American Association for Cancer Research.

26 Aug 2009

University of Maryland researchers perform a genome-wide association study of ADP-stimulated platelet aggregation

Patients with a certain genetic variation who received the antiplatelet drug clopidogrel had a decreased platelet response to treatment and among those who had percutaneous coronary intervention (procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries) had an increased risk of having a cardiovascular event in the following year than patients who did not have this variant, according to a study in the August 26 issue of JAMA.

25 Aug 2009

MicroRNAs present in saliva could be used to detect oral squamous cell carcinoma

A new study published by researchers at the UCLA School of Dentistry substantiates the effectiveness of measuring the microRNAs present in saliva to detect oral squamous cell carcinoma. Like hall monitors in an elementary school, microRNAs are the molecules produced by cells that simultaneously asses the behavior of multiple genes and control their activity.

25 Aug 2009

Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression

Accumulating evidence suggests that connective tissue growth factor (CCN2) plays a central role in fibrotic conditions in many organ systems. Fibrosis is a scarring condition that is characterized by excessive collagen production that impedes normal cell function and can cause organ dysfunction and failure.

25 Aug 2009

Genvec to use $2.5 million grant from NIAID for the development of novel cell lines

GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of GenVec's vector production technology.

25 Aug 2009

The Cancer Center picks ATCi's Simulsat broadcast system to extend its critical broadcast applications

Antenna Technology Communications Inc., a provider of satellite communications systems, today announced that one of the largest university-based cancer research centers has selected the ATCi Simulsat C/Ku Multibeam antenna solution and related satellite equipment to outfit its central headquarters.

25 Aug 2009

Raptor Pharmaceuticals raises funds to execute its corporate strategy

Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has raised an aggregate $5 million of gross proceeds through a private placement of units ("August 2009 Private Placement") and through the exercise of warrants (the "Warrant Exchange") originally issued in connection with its May/June 2008 private placement.

25 Aug 2009

Delcath Systems enrolls 85 patients for its pivotal Phase III Metastatic Melanoma Trial

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that it has exceeded 90% enrollment reaching 85 patients for its pivotal Phase III Metastatic Melanoma Trial.

25 Aug 2009

Shire collaborates with Santaris Pharma to develop Locked Nucleic Acid technology

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business.

25 Aug 2009

University of Manchester researchers discover kinase inhibitors for treating early-stage cancers

University of Manchester researchers found that a special type of the chemicals known as 'kinase inhibitors' opened up communication channels on the surface of cells that enabled healthy cells to 'talk' to the cancer cells.

From The University of Manchester 25 Aug 2009

Cord Blood America announces retirement of $1.6 million in debt since July 2009

Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it has retired $1.6 million in debt since July 2009. The Company previously announced it retired $5 million in debt in the first half of 2009.

25 Aug 2009

MEDRAD and USF sign research agreement to study FDG administration effect on the workflow for PET imaging procedures

...

25 Aug 2009

Cancer News and Research

Latest Cancer News and Research

Lifeline Biotechnologies to establish a demonstration site for its First Warning System

Gloucester Pharmaceuticals raises funds for the development of romidepsin

Increased risk of death for men with heart conditions undergoing RT with hormone therapy for prostate cancer

Duodenal obstruction observed after selective transcatheter arterial embolization for a duodenal diverticular hemorrhage

Tamoxifen drug poses increased risk of developing ER negative breast cancer

Profectus BioSciences to conduct proof-of-concept studies with its rVSV vector technology

Research indicates that acute hepatocellular injury in cholelithiasis and cholecystitis without choledocholithiasis is mild and transient

U.S. Patent Office’s patent issuance provides extensive protection to BDSI's drug delivery technology platforms

MicroRNAs in saliva could aid in the detection of oral cancer

University of Maryland researchers perform a genome-wide association study of ADP-stimulated platelet aggregation

MicroRNAs present in saliva could be used to detect oral squamous cell carcinoma

Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression

Genvec to use $2.5 million grant from NIAID for the development of novel cell lines

The Cancer Center picks ATCi's Simulsat broadcast system to extend its critical broadcast applications

Raptor Pharmaceuticals raises funds to execute its corporate strategy

Delcath Systems enrolls 85 patients for its pivotal Phase III Metastatic Melanoma Trial

Shire collaborates with Santaris Pharma to develop Locked Nucleic Acid technology

University of Manchester researchers discover kinase inhibitors for treating early-stage cancers

Cord Blood America announces retirement of $1.6 million in debt since July 2009

MEDRAD and USF sign research agreement to study FDG administration effect on the workflow for PET imaging procedures

Understanding the DNA Damage Response in Innate Immunity eBook

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Newsletters you may be interested in